L-arginine Effects on Chronic Hypertension in Pregnancy

University of Modena and Reggio Emilia80 enrolled

Overview

The purpose of this study is to evaluate the effects of oral L-arginine administration on pregnant women at second trimester of gestation with chronic hypertension, respect with placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Hypertension in Pregnancy

Interventions

L-arginineDRUG

Oral L-arginine 2 g twice a day for 14 weeks

placeboOTHER

oral placebo 2 g twice a day for 14 weeks

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pregnant women between 18-20 weeks of gestation with chronic hypertension Exclusion Criteria: * Other maternal or fetal systemic disease

Locations (2)

University of Modena and Reggio Emilia

Modena, Emilia-Romagna, Italy

University of Modena and Reggio Emilia

Modena, Mo, Italy

Outcomes

Primary Outcomes

to evaluate blood pressure changes during oral L-arginine or placebo administration in pregnant women with chronic hypertension at second trimester of gestation

Time frame: 14 weeks

Secondary Outcomes

evaluate if is necessary to add a conventional therapy for hypertension, to evaluate pregnancy outcomes and eventual complications, to evaluate safety of oral L-arginine administration

Time frame: 14 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.